ICICI Securities Recommends Buying GlaxoSmithKline Pharmaceuticals, Sets Rs 2,900 Target

ICICI Securities rates GlaxoSmithKline Pharmaceuticals a buy with a Rs 2,900 target. The report says Q2FY27 revenue grew 20.8% year over year, citing a favourable base comparison.